480 related articles for article (PubMed ID: 25342385)
1. 99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen: pharmacokinetics and biodistribution studies in healthy subjects and patients with metastatic prostate cancer.
Vallabhajosula S; Nikolopoulou A; Babich JW; Osborne JR; Tagawa ST; Lipai I; Solnes L; Maresca KP; Armor T; Joyal JL; Crummet R; Stubbs JB; Goldsmith SJ
J Nucl Med; 2014 Nov; 55(11):1791-8. PubMed ID: 25342385
[TBL] [Abstract][Full Text] [Related]
2. 99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen for molecular imaging of prostate cancer.
Hillier SM; Maresca KP; Lu G; Merkin RD; Marquis JC; Zimmerman CN; Eckelman WC; Joyal JL; Babich JW
J Nucl Med; 2013 Aug; 54(8):1369-76. PubMed ID: 23733925
[TBL] [Abstract][Full Text] [Related]
3. Preclinical Evaluation and First Patient Application of 99mTc-PSMA-I&S for SPECT Imaging and Radioguided Surgery in Prostate Cancer.
Robu S; Schottelius M; Eiber M; Maurer T; Gschwend J; Schwaiger M; Wester HJ
J Nucl Med; 2017 Feb; 58(2):235-242. PubMed ID: 27635024
[TBL] [Abstract][Full Text] [Related]
4. PSMA SPECT/CT with
Schmidkonz C; Goetz TI; Kuwert T; Ritt P; Prante O; Bäuerle T; Goebell P; Cordes M
Ann Nucl Med; 2019 Dec; 33(12):891-898. PubMed ID: 31502084
[TBL] [Abstract][Full Text] [Related]
5. Preparation and Biological Evaluation of [
Xiao D; Duan X; Gan Q; Zhang X; Zhang J
Molecules; 2020 Nov; 25(23):. PubMed ID: 33256058
[TBL] [Abstract][Full Text] [Related]
6. Intraindividual Comparison of
Rathke H; Afshar-Oromieh A; Giesel FL; Kremer C; Flechsig P; Haufe S; Mier W; Holland-Letz T; De Bucourt M; Armor T; Babich JW; Haberkorn U; Kratochwil C
J Nucl Med; 2018 Sep; 59(9):1373-1379. PubMed ID: 29371410
[TBL] [Abstract][Full Text] [Related]
7. SPECT/CT With the PSMA Ligand 99mTc-MIP-1404 for Whole-Body Primary Staging of Patients With Prostate Cancer.
Schmidkonz C; Cordes M; Beck M; Goetz TI; Schmidt D; Prante O; Bäuerle T; Uder M; Wullich B; Goebell P; Kuwert T; Ritt P
Clin Nucl Med; 2018 Apr; 43(4):225-231. PubMed ID: 29401151
[TBL] [Abstract][Full Text] [Related]
8.
Schmidkonz C; Hollweg C; Beck M; Reinfelder J; Goetz TI; Sanders JC; Schmidt D; Prante O; Bäuerle T; Cavallaro A; Uder M; Wullich B; Goebell P; Kuwert T; Ritt P
Prostate; 2018 Jan; 78(1):54-63. PubMed ID: 29105797
[TBL] [Abstract][Full Text] [Related]
9. Radiation dosimetry and first therapy results with a (124)I/ (131)I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy.
Zechmann CM; Afshar-Oromieh A; Armor T; Stubbs JB; Mier W; Hadaschik B; Joyal J; Kopka K; Debus J; Babich JW; Haberkorn U
Eur J Nucl Med Mol Imaging; 2014 Jul; 41(7):1280-92. PubMed ID: 24577951
[TBL] [Abstract][Full Text] [Related]
10. Effect of chelators on the pharmacokinetics of (99m)Tc-labeled imaging agents for the prostate-specific membrane antigen (PSMA).
Ray Banerjee S; Pullambhatla M; Foss CA; Falk A; Byun Y; Nimmagadda S; Mease RC; Pomper MG
J Med Chem; 2013 Aug; 56(15):6108-21. PubMed ID: 23799782
[TBL] [Abstract][Full Text] [Related]
11.
Santos-Cuevas C; Davanzo J; Ferro-Flores G; García-Pérez FO; Ocampo-García B; Ignacio-Alvarez E; Gómez-Argumosa E; Pedraza-López M
Nucl Med Biol; 2017 Sep; 52():1-6. PubMed ID: 28575794
[TBL] [Abstract][Full Text] [Related]
12. 99mTc-MIP-1404 SPECT/CT for Patients With Metastatic Prostate Cancer: Interobserver and Intraobserver Variability in Treatment-Related Longitudinal Tracer Uptake Assessments of Prostate-Specific Membrane Antigen-Positive Lesions.
Schmidkonz C; Atzinger A; Goetz TI; Beck M; Ritt P; Prante O; Kuwert T; Bäuerle T; Cordes M
Clin Nucl Med; 2020 Feb; 45(2):105-112. PubMed ID: 31876822
[TBL] [Abstract][Full Text] [Related]
13.
Xu X; Zhang J; Hu S; He S; Bao X; Ma G; Luo J; Cheng J; Zhang Y
Nucl Med Biol; 2017 May; 48():69-75. PubMed ID: 28273495
[TBL] [Abstract][Full Text] [Related]
14. Development of (99m)Tc-labeled asymmetric urea derivatives that target prostate-specific membrane antigen for single-photon emission computed tomography imaging.
Kimura H; Sampei S; Matsuoka D; Harada N; Watanabe H; Arimitsu K; Ono M; Saji H
Bioorg Med Chem; 2016 May; 24(10):2251-6. PubMed ID: 27073053
[TBL] [Abstract][Full Text] [Related]
15. Clinical translation of a PSMA inhibitor for
Ferro-Flores G; Luna-Gutiérrez M; Ocampo-García B; Santos-Cuevas C; Azorín-Vega E; Jiménez-Mancilla N; Orocio-Rodríguez E; Davanzo J; García-Pérez FO
Nucl Med Biol; 2017 May; 48():36-44. PubMed ID: 28193503
[TBL] [Abstract][Full Text] [Related]
16. The Value of
Su HC; Zhu Y; Hu SL; Liu C; Lin GW; Dai B; Zhang YJ; Ye DW
Ann Surg Oncol; 2019 Feb; 26(2):653-659. PubMed ID: 30324468
[TBL] [Abstract][Full Text] [Related]
17. The Rise of PSMA Ligands for Diagnosis and Therapy of Prostate Cancer.
Afshar-Oromieh A; Babich JW; Kratochwil C; Giesel FL; Eisenhut M; Kopka K; Haberkorn U
J Nucl Med; 2016 Oct; 57(Suppl 3):79S-89S. PubMed ID: 27694178
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic sensitivity of Tc-99m HYNIC PSMA SPECT/CT in prostate carcinoma: A comparative analysis with Ga-68 PSMA PET/CT.
Lawal IO; Ankrah AO; Mokgoro NP; Vorster M; Maes A; Sathekge MM
Prostate; 2017 Aug; 77(11):1205-1212. PubMed ID: 28649735
[TBL] [Abstract][Full Text] [Related]
19. Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer.
Hillier SM; Maresca KP; Femia FJ; Marquis JC; Foss CA; Nguyen N; Zimmerman CN; Barrett JA; Eckelman WC; Pomper MG; Joyal JL; Babich JW
Cancer Res; 2009 Sep; 69(17):6932-40. PubMed ID: 19706750
[TBL] [Abstract][Full Text] [Related]
20. Dosimetry estimation and preliminary clinical application of [
Yang H; Gao Z; Xu X; Liu C; Hu S; Zhang J; Song S
Ann Nucl Med; 2023 Jan; 37(1):60-69. PubMed ID: 36346503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]